Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120

Zhiwei Wu, Donald Van Ryk, Cheryl Davis, William R. Abrams, Irwin Chaiken, John Magnani, Daniel Malamud

Research output: Contribution to journalArticle

Abstract

Salivary agglutinin (SAG) is a high molecular mass glycoprotein (340 kDa) that plays important roles in innate immunity. SAG has been found to specifically inhibit HIV-1 infectivity and to bind to virus through the envelope protein gp120. Although SAG binds to gp120 of the virus, the exact nature of this binding has not been characterized. Using surface plasmon resonance technology, we have found that SAG interacts with recombinant envelopes derived from diverse HIV-1 isolates with KD values ranging from 10-7 to 10-10 M, comparable to gp120-sCD4 binding. Furthermore, SAG binding to gp120 is Ca2+ dependent, sCD4 prebound to gp120 failed to abrogate SAG binding, suggesting a distinct mechanism for SAG inhibition of HIV-1 infectivity. Inhibition by monoclonal antibodies specific for carbohydrates also implicates the involvement of carbohydrates in the interaction between SAG and gp120. These results argue that the anti-HIV-1 activity of SAG is due to carbohydrate-mediated binding to gp120. A demonstration that SAG is related to lung scavenger receptor, gp-340, further suggests the roles of SAG in preventing pathogen invasion at the entry portal and raises its potential as an anti-HIV-1 drug candidate.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume19
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Agglutinins
HIV-1
Glycoproteins
Carbohydrates
Viral Envelope Proteins
Anti-HIV Agents
Scavenger Receptors
Surface Plasmon Resonance
Innate Immunity
Monoclonal Antibodies
Viruses
Technology

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. / Wu, Zhiwei; Van Ryk, Donald; Davis, Cheryl; Abrams, William R.; Chaiken, Irwin; Magnani, John; Malamud, Daniel.

In: AIDS Research and Human Retroviruses, Vol. 19, No. 3, 01.03.2003, p. 201-209.

Research output: Contribution to journalArticle

Wu, Zhiwei ; Van Ryk, Donald ; Davis, Cheryl ; Abrams, William R. ; Chaiken, Irwin ; Magnani, John ; Malamud, Daniel. / Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. In: AIDS Research and Human Retroviruses. 2003 ; Vol. 19, No. 3. pp. 201-209.
@article{5c5aa1ad5eb548f1bc135e4c695d94a5,
title = "Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120",
abstract = "Salivary agglutinin (SAG) is a high molecular mass glycoprotein (340 kDa) that plays important roles in innate immunity. SAG has been found to specifically inhibit HIV-1 infectivity and to bind to virus through the envelope protein gp120. Although SAG binds to gp120 of the virus, the exact nature of this binding has not been characterized. Using surface plasmon resonance technology, we have found that SAG interacts with recombinant envelopes derived from diverse HIV-1 isolates with KD values ranging from 10-7 to 10-10 M, comparable to gp120-sCD4 binding. Furthermore, SAG binding to gp120 is Ca2+ dependent, sCD4 prebound to gp120 failed to abrogate SAG binding, suggesting a distinct mechanism for SAG inhibition of HIV-1 infectivity. Inhibition by monoclonal antibodies specific for carbohydrates also implicates the involvement of carbohydrates in the interaction between SAG and gp120. These results argue that the anti-HIV-1 activity of SAG is due to carbohydrate-mediated binding to gp120. A demonstration that SAG is related to lung scavenger receptor, gp-340, further suggests the roles of SAG in preventing pathogen invasion at the entry portal and raises its potential as an anti-HIV-1 drug candidate.",
author = "Zhiwei Wu and {Van Ryk}, Donald and Cheryl Davis and Abrams, {William R.} and Irwin Chaiken and John Magnani and Daniel Malamud",
year = "2003",
month = "3",
day = "1",
doi = "10.1089/088922203763315704",
language = "English (US)",
volume = "19",
pages = "201--209",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120

AU - Wu, Zhiwei

AU - Van Ryk, Donald

AU - Davis, Cheryl

AU - Abrams, William R.

AU - Chaiken, Irwin

AU - Magnani, John

AU - Malamud, Daniel

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Salivary agglutinin (SAG) is a high molecular mass glycoprotein (340 kDa) that plays important roles in innate immunity. SAG has been found to specifically inhibit HIV-1 infectivity and to bind to virus through the envelope protein gp120. Although SAG binds to gp120 of the virus, the exact nature of this binding has not been characterized. Using surface plasmon resonance technology, we have found that SAG interacts with recombinant envelopes derived from diverse HIV-1 isolates with KD values ranging from 10-7 to 10-10 M, comparable to gp120-sCD4 binding. Furthermore, SAG binding to gp120 is Ca2+ dependent, sCD4 prebound to gp120 failed to abrogate SAG binding, suggesting a distinct mechanism for SAG inhibition of HIV-1 infectivity. Inhibition by monoclonal antibodies specific for carbohydrates also implicates the involvement of carbohydrates in the interaction between SAG and gp120. These results argue that the anti-HIV-1 activity of SAG is due to carbohydrate-mediated binding to gp120. A demonstration that SAG is related to lung scavenger receptor, gp-340, further suggests the roles of SAG in preventing pathogen invasion at the entry portal and raises its potential as an anti-HIV-1 drug candidate.

AB - Salivary agglutinin (SAG) is a high molecular mass glycoprotein (340 kDa) that plays important roles in innate immunity. SAG has been found to specifically inhibit HIV-1 infectivity and to bind to virus through the envelope protein gp120. Although SAG binds to gp120 of the virus, the exact nature of this binding has not been characterized. Using surface plasmon resonance technology, we have found that SAG interacts with recombinant envelopes derived from diverse HIV-1 isolates with KD values ranging from 10-7 to 10-10 M, comparable to gp120-sCD4 binding. Furthermore, SAG binding to gp120 is Ca2+ dependent, sCD4 prebound to gp120 failed to abrogate SAG binding, suggesting a distinct mechanism for SAG inhibition of HIV-1 infectivity. Inhibition by monoclonal antibodies specific for carbohydrates also implicates the involvement of carbohydrates in the interaction between SAG and gp120. These results argue that the anti-HIV-1 activity of SAG is due to carbohydrate-mediated binding to gp120. A demonstration that SAG is related to lung scavenger receptor, gp-340, further suggests the roles of SAG in preventing pathogen invasion at the entry portal and raises its potential as an anti-HIV-1 drug candidate.

UR - http://www.scopus.com/inward/record.url?scp=0344405721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344405721&partnerID=8YFLogxK

U2 - 10.1089/088922203763315704

DO - 10.1089/088922203763315704

M3 - Article

VL - 19

SP - 201

EP - 209

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 3

ER -